A phase II study of erlotinib (E) and bevacizumab (B) in chemo naive patients (pts) with locally advanced or metastatic non small cell lung cancer (NSCLC): Predictive value of molecular imaging

8055 Background: In advanced NSCLC, E and B either as a single agent (E) or in combination with chemotherapy (B) have shown to improve survival. Combinations of targeted agents may prove to be effe...